SHANGHAI JUNSHI BIO YC1 (F:8SJ) — Market Cap & Net Worth
Market Cap & Net Worth: SHANGHAI JUNSHI BIO YC1 (8SJ)
SHANGHAI JUNSHI BIO YC1 (F:8SJ) has a market capitalization of $541.68 Million (€463.33 Million) as of June 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #11956 globally and #1315 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANGHAI JUNSHI BIO YC1's stock price €1.78 by its total outstanding shares 260295700 (260.30 Million). Review SHANGHAI JUNSHI BIO YC1 (8SJ) total liabilities to assess the company's total debt and financial obligations.
SHANGHAI JUNSHI BIO YC1 Market Cap History: 2022 to 2026
SHANGHAI JUNSHI BIO YC1's market capitalization history from 2022 to 2026. Data shows change from $1.44 Billion to $541.68 Million (-24.11% CAGR).
SHANGHAI JUNSHI BIO YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANGHAI JUNSHI BIO YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.27x
SHANGHAI JUNSHI BIO YC1's market cap is 0.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.44 Billion | $1.45 Billion | -$2.39 Billion | 0.99x | N/A |
| 2023 | $791.21 Million | $1.50 Billion | -$2.28 Billion | 0.53x | N/A |
| 2024 | $423.00 Million | $1.95 Billion | -$1.28 Billion | 0.22x | N/A |
| 2025 | $681.66 Million | $2.50 Billion | -$840.91 Million | 0.27x | N/A |
Competitor Companies of 8SJ by Market Capitalization
Companies near SHANGHAI JUNSHI BIO YC1 in the global market cap rankings as of June 20, 2026.
Key companies related to SHANGHAI JUNSHI BIO YC1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
SHANGHAI JUNSHI BIO YC1 Historical Marketcap From 2022 to 2026
Between 2022 and today, SHANGHAI JUNSHI BIO YC1's market cap moved from $1.44 Billion to $ 541.68 Million, with a yearly change of -24.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €541.68 Million | -20.54% |
| 2025 | €681.66 Million | +61.15% |
| 2024 | €423.00 Million | -46.54% |
| 2023 | €791.21 Million | -45.15% |
| 2022 | €1.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of SHANGHAI JUNSHI BIO YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $541.68 Million USD |
| MoneyControl | $541.68 Million USD |
| MarketWatch | $541.68 Million USD |
| marketcap.company | $541.68 Million USD |
| Reuters | $541.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more